The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...
AccurEdit Therapeutics today announced that its innovative in vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA).
The first-of-its-kind facility in India has received an investment of $75 million from the company to build it vertically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback